|
|
|
Volumn 8, Issue 3, 2002, Pages 691-697
|
|
A Phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors
c
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIEMETIC AGENT;
DNA TOPOISOMERASE;
DNA TOPOISOMERASE (ATP HYDROLYSING);
DOXORUBICIN;
GLUCOCORTICOID;
GRANULOCYTE COLONY STIMULATING FACTOR;
HYCAMPTIN;
NARCOTIC AGENT;
NONSTEROID ANTIINFLAMMATORY AGENT;
TOPOTECAN;
ADENOCARCINOMA;
ADULT;
ALOPECIA;
ARTICLE;
BOLUS INJECTION;
CLINICAL ARTICLE;
CLINICAL TRIAL;
DRUG TARGETING;
ESOPHAGUS CANCER;
FATIGUE;
FEMALE;
HEART FUNCTION;
HUMAN;
KIDNEY FUNCTION;
LIVER FUNCTION;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
LUNG SMALL CELL CANCER;
MALE;
MAXIMUM TOLERATED DOSE;
NAUSEA;
NEUTROPENIA;
NONHODGKIN LYMPHOMA;
OVARY CANCER;
OVARY CARCINOMA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
SOLID TUMOR;
VOMITING;
ADULT;
AGED;
ANTIGENS, NEOPLASM;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AREA UNDER CURVE;
DNA PRIMERS;
DNA TOPOISOMERASES, TYPE I;
DNA TOPOISOMERASES, TYPE II;
DNA TOPOISOMERASES, TYPE II, EUKARYOTIC;
DNA-BINDING PROTEINS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOXORUBICIN;
ESOPHAGEAL NEOPLASMS;
FEMALE;
HUMANS;
INFUSIONS, INTRAVENOUS;
LUNG NEOPLASMS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
NEOPLASM RECURRENCE, LOCAL;
OVARIAN NEOPLASMS;
REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;
RNA, MESSENGER;
RNA, NEOPLASM;
SAFETY;
TOPOTECAN;
TREATMENT OUTCOME;
|
|
EID: 0036307686
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (23)
|
|
References (31)
|
